Choline (bitartrate vs alpha-GPC vs phosphatidylcholine) trials recruiting now
7 registrations that name choline as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 7 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 7 registrations
RecruitingNCT06527391
Choline and Iron Deficiency
Phase 2 and 3
University of Minnesota
About 300 people
Started Aug 11, 2025
In plain words A Phase 2 and 3 study of choline in people 5 months to 7 months, run by University of Minnesota. It plans to enroll about 300 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 5 months to 7 months. Conditions: Pediatric Iron Deficiency; Anemia.
Age 6 months +/- 28 days
Hb < 11.0 g/dL
ZPP > = 80
T<37.5°C
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
choline bitartrate; placebo drug
Registered summary
BACKGROUND: Iron deficiency limits the neurodevelopmental potential of more than 200 million children each year. Iron therapy is typically started when iron deficiency anemia is first diagnosed after screening for anemia or detection of clinical symptoms of iron deficiency anemia at 12 months of age. But iron started at this time does not fully correct earlier iron-deficiency-mediated brain dysfunction, underscoring the need for low-cost, easily implementable adjunct therapies to iron to treat or prevent this dysfunction in high-risk populations. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06379971
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development
Phase 1
University of Colorado, Denver
About 140 people
Started Nov 25, 2024
In plain words A Phase 1 study of choline in female participants 18 to 45, run by University of Colorado, Denver. It plans to enroll about 140 people at 1 US site.
Pregnant women who report cannabis use during current pregnancy
The exclusion criteria are on the listing.
What it tests, as registered
Placebo; Choline
Registered summary
The goal of this study is to determine if providing a nutritional supplement, phosphatidylcholine, to pregnant women who have used cannabis products during the current pregnancy improves the offspring\'s brain-related development during the first 3 months. Participating pregnant women will receive either phosphatidylcholine or a placebo from approximately 16 weeks gestation through birth. The primary outcomes are the child\'s brain responses to sound at 4 weeks corrected age and infant behaviors at 3 months corrected age as reported by the primary caregiver. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT04395196
RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure
Phase 2
Wayne State University
About 288 people
Started Apr 13, 2023
In plain words A Phase 2 study of choline in people 18 to 45, run by Wayne State University. It plans to enroll about 288 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Fetal Alcohol Spectrum Disorders; Fetal Alcohol Syndrome.
Age ≥18 yr
≤20 wk gestation
Singleton pregnancy
Currently heavy drinking (average of ≥15 ml AA/day or binge drinking (≥4 standard drinks/occasion) on at least 1.5 occasions/month on average since becoming pregnant)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Choline bitartrate; Placebo
Registered summary
Although the adverse effects associated with prenatal alcohol exposure (PAE) are well known, many women continue to drink heavily during pregnancy, putting their infants at risk for fetal alcohol spectrum disorders. Animal studies have shown that choline supplementation can mitigate effects of PAE on growth and development. Choline, an essential nutrient, serves as a methyl-group donor for DNA methylation and is a constituent of the neurotransmitter acetylcholine and a precursor to major components of cell membranes. The full summary is on the listing.
Where, as registered
No US site; South Africa (1).
RecruitingNCT05076682
Reverse Triple Negative Immune Resistant Breast Cancer
Phase 2
Fudan University
About 80 people
Started Jun 30, 2022
In plain words A Phase 2 study of choline in female participants 18 to 70, run by Fudan University. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 70. Conditions: Triple-negative Breast Cancer.
ECOG Performance Status of 0, 1, or 2
Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
Radiologic/objective evidence of recurrence or disease progression after immunotherapy(combined with targeted therapy or chemo ) for metastatic breast cancer(MBC)
Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.
3 more inclusion criteria and the exclusion criteria are on the listing.
This is a Phase II, open-label, seven-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline) with immune checkpoint inhibitor or immune checkpoint inhibitor rechallenge(AK131) in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.
Where, as registered
No US site; China (1).
RecruitingNCT05365425
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Phase 4
Seoul National University Bundang Hospital
About 56 people
Started Jun 1, 2023
In plain words A Phase 4 study of choline in people 20 and older, run by Seoul National University Bundang Hospital. It plans to enroll about 56 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Dyslipidemia; Atherosclerosis; Diabetes Mellitus, Type 2.
Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit
Male or female of 20 years or over
Mixed dyslipidemia: triglyceride 200~499 mg/dL, HDL-cholesterol male ≤45 mg/dL or female ≤50 mg/dL
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Choline fenofibrate; Policosanol
Registered summary
This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.
Where, as registered
No US site; South Korea (1).
RecruitingNCT07699393
Pilot Study of Prenatal Choline Supplementation
Phase 2
Wayne State University
About 50 people
Starts Jul 8, 2026 (estimated)
In plain words A Phase 2 study of choline in people 18 to 45, run by Wayne State University. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Brain Development; Choline Nutrition.
Age ≥18 yr
≤20 wk gestation
Singleton pregnancy
Abstinence from alcohol since conception (by report)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Placebo; Choline bitartrate
Registered summary
A double-blind, randomized, placebo-controlled trial (RCT; NCT04395196) of prenatal choline supplementation is ongoing (1) to assess the effectiveness of maternal choline supplementation during pregnancy to mitigate effects of PAE on three primary outcomes: infant recognition memory and postnatal growth restriction (weight and head circumference); (2) to assess the efficacy of this supplementation for mitigating alcohol effects on the following secondary outcomes: infant eyeblink conditioning, postnatal length, and information processing speed. The full summary is on the listing.
Where, as registered
No US site; South Africa (1).
Not yet recruitingNCT07685613
A Virtual Clinical Trial to Examine the Effect of Magnesium Choline Citrate on Cognitive Function and Anxiety in Healthy Adolescents and Adults
No phase
Nutrisol, LLC
About 200 people
Starts Nov 2026 (estimated)
In plain words A study of choline in people 9 and older, run by Nutrisol, LLC. It plans to enroll about 200 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 9 and older; healthy volunteers accepted. Conditions: Cognitive Function; Anxiety.
Males and females 9 years and older
Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g.
Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
Double-barrier method
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Magnesium Choline Citrate; Placebo
Registered summary
The goal of this clinical trial is to examine the effect of Magnesium Choline Citrate on cognitive function and anxiety in healthy adolescents and adults. The main questions it aims to answer are: * What is the change in cognitive function, as assessed by the PROMIS Cognitive Function- Short Form 8a (≥18 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? * What is the change in cognitive function, as assessed by the Pediatric Cognitive Function - Short Form 7a (9 - 17 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? Researchers… The full summary is on the listing.